" class="no-js "lang="en-US"> Marco Bonesini - Medtech Alert
Saturday, September 23, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Marco Bonesini

Marco Bonesini

About Marco Bonesini

Mr. Bonesini is Chairman and CEO and founder Trueblue. Mr. Bonesini was previously Chairman and CEO and founder of Bluechip Systems, which was acquired by IBM Canada in January 2000. Founded in 1993, Bluechip Systems was a European leader in CRM operative and analytical application software for the Pharmaceutical industry, with over 100 customers.

Related Story

Industry News

 Angelini Pharma and Trueblue: a new collaboration gets underway for optimising data-based decision making and analytics | Pharmtech Focus

Angelini Pharma and Trueblue: a new collaboration gets underway for optimising data-based decision making and analytics

February 10 2021

Promoting the development of corporate decision-making process powered by the use of data, KPIs and […]